[Pharmacokinetics study of amoxicillin sodium clavulanate potassium (10:1) injection in healthy volunteers]. 2013

Jia Miao, and Feng Nan, and Qi Shen, and Yong-Ping Qin, and Ying Wang, and Qin Yu, and Li Zheng, and Mao-Zhi Liang
Clinical Research Unit, West China Hospital, Sichuan University, Chengdu 610041, China.

OBJECTIVE To study the pharmacokinetics of amoxicillin sodium clavulanate potassium (10:1) injection with different single doses intravenous infusion and one dose repeated intravenous injection in healthy volunteers for guiding the rational clinical regimen. METHODS Using infusion pump constantly intravenous dripping in 30 min, 4 mL blood samples were collected before and after the administration at 10 min, 20 min, 30 min, 45 min, and 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10 h. The plasma concentrations of amoxicillin and clavulanate were detected by high performance liquid chromatography- mass spectrometry/mass spectrometry method. The pharmacokinetic parameters were calculated by DAS2.0.1 software. RESULTS The dispositions of amoxicillin and clavulanate matched three or two compartment model with the weight coefficient 1/cc. To avoid the biases caused by compartment model fitting, the pharmacokinetic parameters were statistical moment parameters of non-compartment model. The peak concentrations, the areas under curve, the half-lifes and the clearances after single injections of 0. 55 g, 1.1 g and 2.2 g indicated that both amoxillin and clavulanate had linear dynamics characteristics. After 1.1 g single dose and multiple doses infusion, the pharmacokinetic parameters of amoxicillin and clavulanate were close respectively, and the trough concentrations before the 7th to 13th administration were lower than the detection limitation, which implied that the previous administration had cleared out before the next administration, and no accumulation happened after multiple doses. CONCLUSIONS The amoxicillin sodium clavulanate potassium (10:1) injection possesses the linear kinetics. The dosage regimen of 1.1 g Q8h intravenous infusion could meet the needs of clinical therapy.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D053719 Tandem Mass Spectrometry A mass spectrometry technique using two (MS/MS) or more mass analyzers. With two in tandem, the precursor ions are mass-selected by a first mass analyzer, and focused into a collision region where they are then fragmented into product ions which are then characterized by a second mass analyzer. A variety of techniques are used to separate the compounds, ionize them, and introduce them to the first mass analyzer. For example, for in GC-MS/MS, GAS CHROMATOGRAPHY-MASS SPECTROMETRY is involved in separating relatively small compounds by GAS CHROMATOGRAPHY prior to injecting them into an ionization chamber for the mass selection. Mass Spectrometry-Mass Spectrometry,Mass Spectrometry Mass Spectrometry,Mass Spectrometry, Tandem
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults
D019980 Amoxicillin-Potassium Clavulanate Combination A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate. Amoxicillin-Clavulanic Acid,Potassium Clavulanate-Amoxicillin Combination,Amox-clav,Amoxi-Clavulanate,Amoxycillin-Clavulanic Acid,Augmentin,BRL-25000,Clavulanate Potentiated Amoxycillin,Clavulin,Co-amoxiclav,Coamoxiclav,Spektramox,Synulox,Amox clav,Amoxi Clavulanate,Amoxicillin Clavulanic Acid,Amoxicillin Potassium Clavulanate Combination,Amoxycillin Clavulanic Acid,Amoxycillin, Clavulanate Potentiated,BRL 25000,BRL25000,Co amoxiclav,Potassium Clavulanate Amoxicillin Combination
D064368 Healthy Volunteers Persons with no known significant health problems who are recruited to participate in research to test a new drug, device, or intervention as controls for a patient group. (from http://clinicalcenter.nih.gov/recruit/volunteers.html, accessed 2/14/2013) Healthy Participants,Healthy Subjects,Human Volunteers,Normal Volunteers,Healthy Participant,Healthy Subject,Healthy Volunteer,Human Volunteer,Normal Volunteer,Participant, Healthy,Participants, Healthy,Subject, Healthy,Subjects, Healthy,Volunteer, Healthy,Volunteer, Human,Volunteer, Normal,Volunteers, Human,Volunteers, Normal

Related Publications

Jia Miao, and Feng Nan, and Qi Shen, and Yong-Ping Qin, and Ying Wang, and Qin Yu, and Li Zheng, and Mao-Zhi Liang
January 2002, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban,
Jia Miao, and Feng Nan, and Qi Shen, and Yong-Ping Qin, and Ying Wang, and Qin Yu, and Li Zheng, and Mao-Zhi Liang
April 1982, Antimicrobial agents and chemotherapy,
Jia Miao, and Feng Nan, and Qi Shen, and Yong-Ping Qin, and Ying Wang, and Qin Yu, and Li Zheng, and Mao-Zhi Liang
April 1989, Gastroenterology,
Jia Miao, and Feng Nan, and Qi Shen, and Yong-Ping Qin, and Ying Wang, and Qin Yu, and Li Zheng, and Mao-Zhi Liang
October 1996, The Pediatric infectious disease journal,
Jia Miao, and Feng Nan, and Qi Shen, and Yong-Ping Qin, and Ying Wang, and Qin Yu, and Li Zheng, and Mao-Zhi Liang
November 2020, International journal of clinical pharmacology and therapeutics,
Jia Miao, and Feng Nan, and Qi Shen, and Yong-Ping Qin, and Ying Wang, and Qin Yu, and Li Zheng, and Mao-Zhi Liang
September 1995, Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao,
Jia Miao, and Feng Nan, and Qi Shen, and Yong-Ping Qin, and Ying Wang, and Qin Yu, and Li Zheng, and Mao-Zhi Liang
November 2022, Clinical pharmacology in drug development,
Jia Miao, and Feng Nan, and Qi Shen, and Yong-Ping Qin, and Ying Wang, and Qin Yu, and Li Zheng, and Mao-Zhi Liang
July 1997, Journal of pharmaceutical sciences,
Jia Miao, and Feng Nan, and Qi Shen, and Yong-Ping Qin, and Ying Wang, and Qin Yu, and Li Zheng, and Mao-Zhi Liang
January 2002, Clinical pharmacokinetics,
Jia Miao, and Feng Nan, and Qi Shen, and Yong-Ping Qin, and Ying Wang, and Qin Yu, and Li Zheng, and Mao-Zhi Liang
July 2020, Pakistan journal of pharmaceutical sciences,
Copied contents to your clipboard!